Astellas and Seattle Genetics Win Accelerated Approval for Bladder Cancer Drug
Merck's Keytruda is bound for new bladder cancer territory. But can it hold up against gene therapy?
5 questions ESMO cancer drug data might answer
Neoadjuvant Pembrolizumab for Muscle-Invasive Bladder Cancer
Roche’s Tecentriq is on a much-needed hot streak. On Tuesday, the immuno-oncology drug—in combination with Roche’s Avastin—picked up a breakthrough therapy designation from the FDA in previously untreated liver cancer patients, putting it on the path to a speedy approval. The agency based the decision on phase 1b data, presented at last month’s American … Συνεχίστε να διαβάζετε Roche’s Tecentriq extends its hot streak with liver cancer combo breakthrough.